Zepbound® (Tirzepatide) Injection — Once-Weekly Weight-Loss Dual-Action Pen

Price range: $299.00 through $589.00

Extra Features
  • Dermatologist Approved
  • Secure Payments
  • Satisfaction Guarantee
  • Worldwide Shipping
  • Money Back Guarantee

Chronic weight management · Obesity-related obstructive sleep apnea · Subcutaneous autoinjector

Zepbound® 2.5 mg — Where Your Weight-Loss Journey Begins
Once-weekly pen · 4-week initiation dose.
Zepbound® 5 mg — Appetite Starts Listening to Two Signals at Once
Once-weekly pen · First maintenance dose.
Zepbound® 7.5 mg — Accelerating the Weight-Loss Curve
Once-weekly pen · Intermediate escalation dose.
Zepbound® 10 mg — High-Performance Weight Management, One Shot a Week
Once-weekly pen · Higher maintenance dose.
Zepbound® 12.5 mg— One Step from the Most Powerful Dose
Once-weekly pen · Penultimate escalation dose.
Zepbound® 15 mg — The Full Force of Two Pathways, Maximum Dose
Once-weekly pen · Maximum approved dose.
Guaranteed Safe Checkout
SKU: N/A Categories: ,
First four weeks — introducing tirzepatide’s dual-action blueprint for weight loss. A calm, measured start with a powerful finish ahead.
Zepbound® 2.5 mg tirzepatide is the four-week initiation dose for chronic weight management, activating both GIP and GLP-1 receptors to ease the body into sustained dual incretin therapy. Administered once weekly via subcutaneous autoinjector pen for self-injection.
The first maintenance milestone. Hunger is responding to dual-receptor activity — and the scale begins to reflect it.
Zepbound® 5 mgtirzepatide is the initial maintenance dose for weight management, with both GIP and GLP-1 pathways now engaged at a therapeutic level. Weekly injections continue building the dual incretin effect that supports meaningful, sustained body weight reduction.
Mid-escalation — where many patients notice their biggest momentum shift. Dual-receptor activity is now running at high capacity.
Zepbound® 7.5 mg tirzepatideoffers an intermediate escalation step in the dose-titration schedule, supporting patients who benefit from gradual advancement toward higher therapeutic doses for chronic weight management and obesity-related conditions.
Significant weekly weight reduction is now underway. Clinical data shows double-digit percentage body weight loss at this level for many patients.
Zepbound® 10 mg tirzepatide delivers high-level dual GIP and GLP-1 agonism once weekly for chronic weight management. In the SURMOUNT trials, this dose contributed to average body weight reductions exceeding 20% in certain patient populations over 72 weeks.
Near-maximum dual-incretin engagement — for patients escalating toward the most potent Zepbound dose available.
Zepbound® 12.5 mg tirzepatide continues the structured dose escalation for weight management with near-peak dual-receptor stimulation. Delivered once weekly via subcutaneous pen, this penultimate dose prepares patients for maximum long-term maintenance therapy.
The highest approved dose for weight loss and sleep apnea. In clinical trials, patients lost an average of 22% of body weight — one injection per week at peak dual-incretin potency.
Zepbound® 15 mg tirzepatide is the maximum approved dose for chronic weight management and obesity-related obstructive sleep apnea. SURMOUNT trial data showed average weight loss of approximately 22.5% of body weight at this dose, administered via once-weekly subcutaneous autoinjector pen for long-term therapy.
Dosage

2.5mg, 5mg, 7.5mg, 10mg, 12.5mg, 15mg

Reviews

There are no reviews yet.

Be the first to review “Zepbound® (Tirzepatide) Injection — Once-Weekly Weight-Loss Dual-Action Pen”

Your email address will not be published. Required fields are marked *